Australia markets open in 3 hours 18 minutes

Mustang Bio, Inc. (MBIO)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.3211+0.0002 (+0.06%)
At close: 04:00PM EDT
0.3186 -0.00 (-0.78%)
After hours: 04:40PM EDT

Mustang Bio, Inc.

377 Plantation Street
1st Floor
Worcester, MA 01605
United States
781 652 4500
https://www.mustangbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees80

Key executives

NameTitlePayExercisedYear born
Mr. Michael S. Weiss Esq.Executive Chairman60kN/A1966
Dr. Manuel Litchman M.D.President, CEO & Director480.79kN/A1954
Mr. James B. MurphyInterim Chief Financial OfficerN/AN/A1957
Mr. Peter CarneyController & Interim Chief Accounting OfficerN/AN/A1987
Mr. Matthew Wein J.D.VP & General CounselN/AN/AN/A
Ms. Debra Manning SPHRSenior VP & Head of Human ResourcesN/AN/AN/A
Ms. Lynn E. Bayless M.S.VP & Head of Regulatory AffairsN/AN/AN/A
Dr. Bruce Dezube M.D.Senior VP & Head of Clinical DevelopmentN/AN/AN/A
Mr. Greg Furrow M.S.Chief Quality OfficerN/AN/AN/A
Mr. Richard Bodmer M.S.Head of CMC DevelopmentN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Corporate governance

Mustang Bio, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.